Page 1754 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 98 Principles of Cell-Based Genetic Therapies 1558.e1

REFERENCES 14. Kang EM, Choi U, Theobald N, et al: Retrovirus gene therapy for
X-linked chronic granulomatous disease can achieve stable long-term
1. Touw IP, Erkeland SJ: Retroviral insertion mutagenesis in mice as a correction of oxidase activity in peripheral blood neutrophils. Blood
comparative oncogenomics tool to identify disease genes in human 115:783–791, 2010.
leukemia. Mol Ther 15:13–19, 2007. 15. Boztug K, Schmidt M, Schwarzer A, et al: Stem-cell gene therapy for the
2. Adair JE, Johnston SK, Mrugala MM, et al: Gene therapy enhances Wiskott-Aldrich syndrome. N Engl J Med 363:1918–1927, 2010.
chemotherapy tolerance and efficacy in glioblastoma patients. J Clin 16. Avedillo Diez I, Zychlinski D, Coci EG, et al: Development of novel
Invest 124:4082–4092, 2014. efficient SIN vectors with improved safety features for Wiskott-Aldrich
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al: Hematopoietic syndrome stem cell based gene therapy. Mol Pharm 8:1525–1537, 2011.
stem cell gene therapy with a lentiviral vector in X-linked adrenoleuko- 17. Braun CJ, Boztug K, Paruzynski A, et al: Gene therapy for Wiskott-
dystrophy. Science 326:818–823, 2009. Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med
4. Cavazzana-Calvo M, Payen E, Negre O, et al: Transfusion independence 6:227ra233, 2014.
and HMGA2 activation after gene therapy of human beta-thalassaemia. 18. Thompson AA, Rasko JE, Hongeng S, et al: Initial results from the
Nature 467:318–322, 2010. Northstar Study (HGB-204): a phase 1/2 study of gene therapy for
5. Suerth JD, Maetzig T, Galla M, et al: Self-inactivating alpharetroviral β-thalassemia major via transplantation of autologous hematopoietic
vectors with a split-packaging design. J Virol 84:6626–6635, 2010. stem cells transduced ex vivo with a lentiviral βΑ-T87Q-globin vector
6. Hacein-Bey-Abina S, Pai SY, Gaspar HB, et al: A modified gamma- (LentiGlobin BB305 Drug Product). Blood (ASH Annual Meeting
retrovirus vector for X-linked severe combined immunodeficiency. N Abstracts) 124:2014.
Engl J Med 371:1407–1417, 2014. 19. Cavazzana M, Ribeil J-A, Payen E, et al: Study Hgb-205: outcomes of
7. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al: Gene gene therapy for hemoglobinopathies via transplantation of autologous
therapy of human severe combined immunodeficiency (SCID)-X1 hematopoietic stem cells transduced ex vivo with a lentiviral βΑ-T87Q-
disease. Science 288:669–672, 2000. Globin Vector (LentiGlobin® BB305 Drug Product). Blood (ASH
8. Gaspar HB, Parsley KL, Howe S, et al: Gene therapy of X-linked severe Annual Meeting Abstracts) 124:2014.
combined immunodeficiency by use of a pseudotyped gammaretroviral 19a. Sankaran VG, Xu J, Ragoczy T, et al: Developmental and species-diver-
vector. Lancet 364:2181–2187, 2004. gent globin switching are driven by BCL11A. Nature 460:1093–1097,
8a. Woods NB, Bottero V, Schmidt M, et al: Gene therapy: therapeutic 2009.
gene causing lymphoma. Nature 440:1123, 2006. 20. Xu J, Peng C, Sankaran VG, et al: Correction of sickle cell disease
9. Sauer AV, Di Lorenzo B, Carriglio N, et al: Progress in gene therapy for in adult mice by interference with fetal hemoglobin silencing. Science
primary immunodeficiencies using lentiviral vectors. Curr Opin Allergy 334:993–996, 2011.
Clin Immunol 14:527–534, 2014. 21. Kohn DB, Sadelain M, Glorioso JC: Occurrence of leukaemia following
10. Trasher AJ, Gaspar B: Successful bone marrow gene therapy for SCID. gene therapy of X-linked SCID. Nat Rev Cancer 3:477–488, 2003.
Blood Cells Mol Dis 40:287–288, 2008. 21a. Wilmut I, Schnieke AE, McWhir J, et al: Viable offspring derived from
10a. Booth C, Hershfield M, Notarangelo L, et al: Management options fetal and adult mammalian cells. Nature 385:810–813, 1997.
for adenosine deaminase deficiency; proceedings of the EBMT satellite 22. Sadelain M, Papapetrou EP, Bushman FD: Safe harbours for the integra-
workshop (Hamburg, March 2006). Clin Immunol 123:139–147, 2007. tion of new DNA in the human genome. Nat Rev Cancer 12:51–58,
11. Aiuti A, Cattaneo F, Galimberti S, et al: Gene therapy for immu- 2012.
nodeficiency due to adenosine deaminase deficiency. N Engl J Med 23. Lombardo A, Genovese P, Beausejour CM, et al: Gene editing in human
360:447–458, 2009. stem cells using zinc finger nucleases and integrase-defective lentiviral
12. Cicalese MP, Aiuti A: Clinical applications of gene therapy for Primary vector delivery. Nat Biotechnol 25:1298–1306, 2007.
Immunodeficiencies. Hum Gene Ther 26:210–219, 2015. 24. Papapetrou EP, Lee G, Malani N, et al: Genomic safe harbors permit
12a. Ott MG, Merget-Millitzer H, Ottmann OG, et al: Mobilization and high beta-globin transgene expression in thalassemia induced pluripotent
transduction of CD34(+) peripheral blood stem cells in patients with stem cells. Nat Biotechnol 29:73–78, 2011.
X-linked chronic granulomatous disease. J Hematother Stem Cell Res 25. Breda L, Rupon JW, Motta I, et al: Comparing strategies to reactivate
11(4):683–694, 2002. fetal globin expression for the treatment of beta-globinopathies. Blood
13. Stein S, Ott MG, Schultze-Strasser S, et al: Genomic instability and (ASH Annual Meeting Abstracts) 124:333, 2014.
myelodysplasia with monosomy 7 consequent to EVI1 activation after 26. Boch J: TALEs of genome targeting. Nat Biotechnol 29:135–136, 2011.
gene therapy for chronic granulomatous disease. Nat Med 16:198–204,
2010.